Observational studyFuture oncology (London, England)2024

Real-world outcomes with fedratinib therapy in patients who discontinued ruxolitinib for primary myelofibrosis.

Francesco Passamonti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.